Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

In two replicate trials, depemokimab, an ultra-long-acting anti–interleukin-5 biologic therapy, reduced exacerbations in patients who had severe asthma with an eosinophilic phenotype.

​   The New England Journal of Medicine: Search Results in Pulmonary/Critical Care